4.4 Anxiolytics, Sedative-Hypnotics & Stimulants

Anxiolytics and sedative-hypnotics relieve acute distress and insomnia, but nearly every agent in this group carries a dependence liability that shapes how it is prescribed and monitored; stimulants used for ADHD raise a parallel set of safety concerns around cardiovascular risk and diversion.

Benzodiazepines

Benzodiazepines (lorazepam, alprazolam, diazepam, clonazepam) enhance GABA-A receptor activity, increasing the frequency of chloride-channel opening and producing rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. They are effective for acute anxiety/panic, alcohol withdrawal, seizures, and procedural sedation — but because of tolerance, physical dependence, and a real withdrawal syndrome, guidelines recommend short-term use whenever possible.

Key safety points:

• Withdrawal seizures: Abruptly stopping a benzodiazepine after regular use can cause a withdrawal syndrome that includes life-threatening seizures; discontinuation requires a gradual taper, never an abrupt stop.
• Reversal agent: Flumazenil is a competitive antagonist at the benzodiazepine binding site and reverses benzodiazepine sedation/overdose. It is used cautiously — in a patient with chronic benzodiazepine dependence or a mixed overdose (especially with a pro-convulsant co-ingestant), flumazenil can precipitate acute withdrawal seizures.
• Respiratory depression: Combining a benzodiazepine with an opioid or other CNS depressant sharply increases the risk of fatal respiratory depression — this combination carries an FDA boxed warning, and the nurse should question co-prescriptions and monitor sedation/respiratory status closely whenever both classes are ordered.

Half-life also shapes clinical use. Short-acting agents (alprazolam, lorazepam) act quickly but carry a higher risk of interdose rebound anxiety and a higher abuse liability, while long-acting agents (diazepam, clonazepam) provide steadier coverage and are often preferred for a supervised taper because blood levels fall more gradually. In patients with hepatic impairment or in older adults, lorazepam, oxazepam, and temazepam ("the LOT drugs") are preferred because they are metabolized by glucuronidation without active metabolites, avoiding drug accumulation — though Beers Criteria still flag benzodiazepines generally as high-risk in older adults for falls, fractures, and cognitive impairment.

Buspirone

Buspirone is a non-benzodiazepine anxiolytic that acts as a partial agonist at serotonin 5-HT1A receptors. It carries minimal abuse or dependence potential and produces no cross-tolerance with benzodiazepines, so it cannot be substituted to treat benzodiazepine withdrawal. Its major teaching point is timing: like an antidepressant, buspirone has a delayed onset of 2-4 weeks and is not effective when taken PRN for acute anxiety — patients expecting immediate relief will be disappointed and may stop the medication prematurely without proper education.

Sedative-Hypnotics ("Z-Drugs")

Zolpidem, zaleplon, and eszopiclone are nonbenzodiazepine hypnotics that act at the same GABA-A benzodiazepine binding site and are used short-term for insomnia. Despite the "non-benzodiazepine" name, they carry a similar dependence potential to benzodiazepines and an FDA boxed warning for complex sleep behaviors — sleepwalking, sleep-driving, and sleep-eating with no memory of the event. Patients should be counseled to take the dose immediately before getting into bed, allow a full night's sleep, and avoid alcohol. Because women clear zolpidem more slowly than men, the FDA lowered the recommended starting dose for women specifically to reduce next-morning impairment and driving risk — a detail worth confirming during medication reconciliation.

Stimulants and Non-Stimulants for ADHD

Stimulants — methylphenidate (e.g., immediate- and extended-release formulations) and amphetamine salts (e.g., mixed amphetamine salts, and lisdexamfetamine, a prodrug with lower misuse potential because it requires enzymatic conversion to become active) — are first-line ADHD treatment and are Schedule II controlled substances with meaningful misuse and diversion risk. Nursing priorities include baseline and periodic monitoring of blood pressure and heart rate (caution in patients with cardiac disease, structural cardiac abnormalities, or a family history of sudden cardiac death), monitoring growth and appetite in children, and assessing for insomnia. Stimulants should never be combined with an MAOI, which can precipitate a hypertensive crisis.

Before starting any benzodiazepine or stimulant, screening for a personal or family history of substance use disorder is an essential nursing step, since both classes carry misuse potential that should shape the prescribing conversation and follow-up frequency.

Non-stimulant alternatives avoid controlled-substance concerns:

• Atomoxetine — a selective norepinephrine reuptake inhibitor; non-controlled, but carries its own black-box warning for suicidal thinking in children and adolescents.
• Guanfacine ER / clonidine ER — alpha-2 agonists; can cause sedation and hypotension/bradycardia; must be tapered, not stopped abruptly, to avoid rebound hypertension.

Clinical Application

A patient prescribed alprazolam for panic disorder for eight months who now wants to stop "cold turkey" needs education on tapering and a same-day discussion with the prescriber — abrupt discontinuation risks withdrawal seizures. A patient started on buspirone who calls after three days saying "it isn't working" is not having treatment failure; the nurse should reinforce the 2-4-week onset and confirm the medication is not being used PRN.